<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02732015</url>
  </required_header>
  <id_info>
    <org_study_id>2015-0587</org_study_id>
    <secondary_id>NCI-2016-00801</secondary_id>
    <secondary_id>2015-0587</secondary_id>
    <nct_id>NCT02732015</nct_id>
  </id_info>
  <brief_title>Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy</brief_title>
  <official_title>Effects of Rolapitant on Nausea/Vomiting in Patients With Sarcoma Receiving Multi-Day Highly Emetogenic Chemotherapy (HEC) With Doxorubicin and Ifosfamide Regimen (AI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well rolapitant hydrochloride works in preventing&#xD;
      nausea/vomiting in patients with sarcoma receiving chemotherapy. Antiemetic drugs, such as&#xD;
      rolapitant hydrochloride, may help control or prevent nausea and vomiting in patients treated&#xD;
      with chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate the effect of rolapitant hydrochloride (rolapitant) on nausea/vomiting in&#xD;
      patients with sarcoma receiving multi-day highly emetogenic chemotherapy (HEC) regimen of&#xD;
      doxorubicin and ifosfamide (AI).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the toxicity of rolapitant in patients receiving AI regimen. II. To evaluate&#xD;
      the effects of rolapitant on patient reported outcomes.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      PART I: Patients receive dexamethasone intravenously (IV) daily and ondansetron IV on days&#xD;
      1-5, and rolapitant hydrochloride orally (PO) on day 1.&#xD;
&#xD;
      PART II: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients receive treatment as in part I. Treatment repeats every 21 days for 6 cycles&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      ARM II: Patients receive dexamethasone IV and ondansetron IV on days 1-5, and fosaprepitant&#xD;
      dimeglumine IV over 30 minutes on days 1 of cycle 2. Treatment repeats every 21 days for 6&#xD;
      cycles in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      CHEMOTHERAPY: All patients receive doxorubicin IV over 72 hours, mesna IV, and ifosfamide IV&#xD;
      over 3 hours on days 1-4 or 1-5. Patients with sarcomas of small cell histology receive&#xD;
      vincristine sulfate IV on day 1. Cycles repeat every 3 weeks following blood count and&#xD;
      patient recovery from any acute toxicities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated per PI's request&#xD;
  </why_stopped>
  <start_date type="Actual">October 12, 2016</start_date>
  <completion_date type="Actual">July 10, 2020</completion_date>
  <primary_completion_date type="Actual">July 10, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Complete Response (CR) of Rolapitant Hydrochloride Administered as a Single-dose</measure>
    <time_frame>Days 1-10</time_frame>
    <description>Complete response (CR) no emetic episodes and no rescue medications.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Locally Advanced Sarcoma</condition>
  <arm_group>
    <arm_group_label>Arm I (rolapitant hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive treatment as in part I. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
CHEMOTHERAPY: All patients receive doxorubicin IV over 72 hours, mesna IV, and ifosfamide IV over 3 hours on days 1-4 or 1-5. Patients with sarcomas of small cell histology receive vincristine sulfate IV on day 1. Cycles repeat every 3 weeks following blood count and patient recovery from any acute toxicities.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (fosaprepitant dimeglumine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive dexamethasone IV and ondansetron IV on days 1-5, and fosaprepitant dimeglumine IV over 30 minutes on days 1 of cycle 2. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
CHEMOTHERAPY: All patients receive doxorubicin IV over 72 hours, mesna IV, and ifosfamide IV over 3 hours on days 1-4 or 1-5. Patients with sarcomas of small cell histology receive vincristine sulfate IV on day 1. Cycles repeat every 3 weeks following blood count and patient recovery from any acute toxicities.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (rolapitant hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (fosaprepitant dimeglumine)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycadron</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decadron DP</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasone Intensol</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>TaperDex</other_name>
    <other_name>Visumetazone</other_name>
    <other_name>ZoDex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (rolapitant hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (fosaprepitant dimeglumine)</arm_group_label>
    <other_name>Adriablastin</other_name>
    <other_name>Hydroxydaunomycin</other_name>
    <other_name>Hydroxyl Daunorubicin</other_name>
    <other_name>Hydroxyldaunorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosaprepitant Dimeglumine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (fosaprepitant dimeglumine)</arm_group_label>
    <other_name>Emend for Injection</other_name>
    <other_name>L-785,298</other_name>
    <other_name>MK-0517</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (rolapitant hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (fosaprepitant dimeglumine)</arm_group_label>
    <other_name>Asta Z 4942</other_name>
    <other_name>Asta Z-4942</other_name>
    <other_name>Cyfos</other_name>
    <other_name>Holoxan</other_name>
    <other_name>Holoxane</other_name>
    <other_name>Ifex</other_name>
    <other_name>IFO</other_name>
    <other_name>IFO-Cell</other_name>
    <other_name>Ifolem</other_name>
    <other_name>Ifomida</other_name>
    <other_name>Ifomide</other_name>
    <other_name>Ifosfamidum</other_name>
    <other_name>Ifoxan</other_name>
    <other_name>IFX</other_name>
    <other_name>Iphosphamid</other_name>
    <other_name>Iphosphamide</other_name>
    <other_name>Iso-Endoxan</other_name>
    <other_name>Isoendoxan</other_name>
    <other_name>Isophosphamide</other_name>
    <other_name>Mitoxana</other_name>
    <other_name>MJF 9325</other_name>
    <other_name>MJF-9325</other_name>
    <other_name>Naxamide</other_name>
    <other_name>Seromida</other_name>
    <other_name>Tronoxal</other_name>
    <other_name>Z 4942</other_name>
    <other_name>Z-4942</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (rolapitant hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (fosaprepitant dimeglumine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (rolapitant hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (fosaprepitant dimeglumine)</arm_group_label>
    <other_name>2-Mercaptoethanesulfonate, Sodium Salt</other_name>
    <other_name>Ausobronc</other_name>
    <other_name>D-7093</other_name>
    <other_name>Filesna</other_name>
    <other_name>Mercaptoethane Sulfonate</other_name>
    <other_name>Mercaptoethanesulfonate</other_name>
    <other_name>Mesnex</other_name>
    <other_name>Mesnil</other_name>
    <other_name>Mesnum</other_name>
    <other_name>Mexan</other_name>
    <other_name>Mistabron</other_name>
    <other_name>Mistabronco</other_name>
    <other_name>Mitexan</other_name>
    <other_name>Mucofluid</other_name>
    <other_name>Mucolene</other_name>
    <other_name>UCB 3983</other_name>
    <other_name>Uromitexan</other_name>
    <other_name>Ziken</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (rolapitant hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (fosaprepitant dimeglumine)</arm_group_label>
    <other_name>Zofran ODT</other_name>
    <other_name>Zuplenz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (rolapitant hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (fosaprepitant dimeglumine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rolapitant Hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (rolapitant hydrochloride)</arm_group_label>
    <other_name>Rolapitant HCl</other_name>
    <other_name>Rolapitant Hydrochloride Monohydrate</other_name>
    <other_name>Rolapitant Monohydrochloride Monohydrate</other_name>
    <other_name>SCH-619734</other_name>
    <other_name>SCH619734</other_name>
    <other_name>Varubi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (rolapitant hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (fosaprepitant dimeglumine)</arm_group_label>
    <other_name>Kyocristine</other_name>
    <other_name>Leurocristine Sulfate</other_name>
    <other_name>Leurocristine, sulfate</other_name>
    <other_name>Oncovin</other_name>
    <other_name>Vincasar</other_name>
    <other_name>Vincosid</other_name>
    <other_name>Vincrex</other_name>
    <other_name>Vincristine, sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with sarcoma which is locally advanced, at high risk for relapse or&#xD;
             metastatic for whom treatment with doxorubicin plus ifosfamide (AI) or AI and&#xD;
             vincristine (VAI) is indicated&#xD;
&#xD;
          -  Patient must have an estimated life expectancy &gt;= 4 months in the opinion of the&#xD;
             investigators&#xD;
&#xD;
          -  Male and females of child bearing potential must use acceptable methods of birth&#xD;
             control which include oral contraceptives, spermicide with either a condom, diaphragm&#xD;
             or cervical cap, use of an intrauterine device (IUD) or abstinence&#xD;
&#xD;
               -  Female patients must have a negative pregnancy test at screening&#xD;
&#xD;
               -  Female patients of childbearing potential must agree to use an acceptable method&#xD;
                  of birth control (excluding hormonal birth control methods) for 72 hours prior to&#xD;
                  admission and to continue its use during the study and for at least 30 days after&#xD;
                  the final dose&#xD;
&#xD;
               -  Male patients must agree to use an acceptable form of birth control from study&#xD;
                  day 1 through at least 30 days after the final dose&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt; 1500/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Serum creatinine &lt; 1.5 mg/dL&#xD;
&#xD;
          -  Serum bilirubin count &lt; 1.5 x upper limit normal (ULN)&#xD;
&#xD;
          -  Serum glutamic-oxaloacetic transaminase (SGOT) or serum glutamate pyruvate&#xD;
             transaminase (SGPT) &lt; 2.5 x ULN; for subjects with known liver metastases &lt; 5 x ULN&#xD;
&#xD;
          -  Karnofsky performance status &gt; 60%&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
          -  Patients are required to read and understand English to comply with protocol&#xD;
             requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any current treatment, medical history, or uncontrolled condition, other than&#xD;
             malignancy, (e.g., alcoholism or signs of alcohol abuse, seizure disorder, medical or&#xD;
             psychiatric condition) that, in the opinion of the investigator, would confound the&#xD;
             results of the study or pose any unwarranted risk in administering study drug to the&#xD;
             subject&#xD;
&#xD;
          -  Patient has a known hypersensitivity to the administration of any prescribed oral or&#xD;
             intravenous study medication or metabolite, including but not limited to, a history of&#xD;
             hypersensitivity to the drugs or their components, severe renal impairment, severe&#xD;
             bone marrow suppression, or systemic infection&#xD;
&#xD;
          -  Patient is a woman with a positive urine or serum pregnancy test within 3 days prior&#xD;
             to study drug administration, is breast-feeding, or is planning to conceive children&#xD;
             within the projected duration of the study treatment&#xD;
&#xD;
          -  Patient has taken the anti-emetic agents within the last 48 hours prior to the start&#xD;
             of treatment with study drug:&#xD;
&#xD;
               -  5-hydroxytryptamine (HT)3 antagonists (ondansetron, granisetron, dolasetron,&#xD;
                  tropisetron, etc.); palonosetron is not permitted within 7 days prior to&#xD;
                  administration of investigational product&#xD;
&#xD;
               -  Phenothiazines (prochlorperazine, fluphenazine, perphenazine, thiethylperazine,&#xD;
                  chlorpromazine, etc.)&#xD;
&#xD;
               -  Benzamides (metoclopramide, alizapride, etc.)&#xD;
&#xD;
               -  Domperidone&#xD;
&#xD;
               -  Cannabinoids&#xD;
&#xD;
               -  Neurokinin (NK)1 antagonist (aprepitant)&#xD;
&#xD;
               -  Benzodiazepines (lorazepam, alprazolam, etc)&#xD;
&#xD;
               -  Herbal medications or preparations in doses designed to ameliorate nausea or&#xD;
                  emesis&#xD;
&#xD;
          -  Patient has received systemic corticosteroids or sedative antihistamines&#xD;
             (dimenhydrinate, diphenhydramine, etc.) within 72 hours of day 1 of the study except&#xD;
             as premedication for chemotherapy (e.g., taxanes); subjects who are receiving inhaled&#xD;
             steroids for respiratory conditions or topical steroids for skin disorders can be&#xD;
             enrolled&#xD;
&#xD;
          -  Patient has symptomatic primary or metastatic central nervous system (CNS) disease&#xD;
&#xD;
          -  Patient has ongoing vomiting, retching, dry heaves, or clinically significant nausea&#xD;
             caused by any etiology, or has had such symptoms within 24 hours prior to the start of&#xD;
             day 1 of the study intervention, or has a history of anticipatory nausea and vomiting&#xD;
&#xD;
          -  Patient must not have been dosed with test drug or blinded study drug in another&#xD;
             investigational study within 30 days or 5 half-lives of the biologic activity of the&#xD;
             test drug, whichever is longer, before the time of first study dose&#xD;
&#xD;
          -  Patient who is participating in any investigational agent that is not Food and Drug&#xD;
             Administration (FDA)-approved&#xD;
&#xD;
          -  Patient has uncontrolled angina, congestive heart failure (New York Heart Association&#xD;
             &gt; class II or known ejection fraction &lt; 40%), uncontrolled cardiac arrhythmia or&#xD;
             hypertension, or acute myocardial infarction within 3 months&#xD;
&#xD;
          -  Prior surgery or radiotherapy (RT) within 2 weeks of study entry&#xD;
&#xD;
          -  Psychological, social, familial, or geographical reasons that would prevent scheduled&#xD;
             visits and follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saroj Vadhan</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 4, 2016</study_first_submitted>
  <study_first_submitted_qc>April 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2016</study_first_posted>
  <results_first_submitted>July 6, 2021</results_first_submitted>
  <results_first_submitted_qc>August 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 9, 2021</results_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Rolapitant</mesh_term>
    <mesh_term>Mesna</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 28, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02732015/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 37 participants were consented, 1 screen failure. protocol terminated early only part I of the protocol was completed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1</title>
          <description>Dexamethasone IV daily for 5 days (12 mg on day 1 and 8 mg on days 2-5), Ondansetron (5HT3 receptor antagonist) 16 mg IV daily for 5 days as standard of care, and Rolapitant, 180 mg was administered PO on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2</title>
          <description>Dexamethasone IV daily for 5 days (12 mg on days 1-5 ), Ondansetron (5HT3 receptor antagonist) 16 mg IV daily for 5 days as standard of care, and Rolapitant, 180 mg was administered PO on Day 1</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1 - 8mg Dexamethasone</title>
          <description>Dexamethasone IV daily for 5 days (12 mg on day 1 and 8 mg on days 2-5), Ondansetron (5HT3 receptor antagonist) 16 mg IV daily for 5 days as standard of care, and Rolapitant, 180 mg was administered PO on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2- 12mg Dexamethasone</title>
          <description>Dexamethasone IV daily for 5 days (12 mg on days 1-5 ), Ondansetron (5HT3 receptor antagonist) 16 mg IV daily for 5 days as standard of care, and Rolapitant, 180 mg was administered PO on Day 1</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" lower_limit="24" upper_limit="60"/>
                    <measurement group_id="B2" value="38" lower_limit="19" upper_limit="59"/>
                    <measurement group_id="B3" value="38" lower_limit="19" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Complete Response (CR) of Rolapitant Hydrochloride Administered as a Single-dose</title>
        <description>Complete response (CR) no emetic episodes and no rescue medications.</description>
        <time_frame>Days 1-10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Dexamethasone IV daily for 5 days (12 mg on day 1 and 8 mg on days 2-5), Ondansetron (5HT3 receptor antagonist) 16 mg IV daily for 5 days as standard of care, and Rolapitant, 180 mg was administered PO on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Dexamethasone IV daily for 5 days (12 mg on days 1-5 ), Ondansetron (5HT3 receptor antagonist) 16 mg IV daily for 5 days as standard of care, and Rolapitant, 180 mg was administered PO on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Response (CR) of Rolapitant Hydrochloride Administered as a Single-dose</title>
          <description>Complete response (CR) no emetic episodes and no rescue medications.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>collected from the time of informed consent to 30 days after last study drug administration, up to 10 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1</title>
          <description>Dexamethasone IV daily for 5 days (12 mg on day 1 and 8 mg on days 2-5), Ondansetron (5HT3 receptor antagonist) 16 mg IV daily for 5 days as standard of care, and Rolapitant, 180 mg was administered PO on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2</title>
          <description>Dexamethasone IV daily for 5 days (12 mg on days 1-5 ), Ondansetron (5HT3 receptor antagonist) 16 mg IV daily for 5 days as standard of care, and Rolapitant, 180 mg was administered PO on Day 1</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.03)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Chest tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Rapid heart rate</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Rectal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Rectal tear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Uncontrolled pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Throat pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Electrolytes imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>CTCAE (4.03)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Saroj Vadhan,MD-Clinical Professor, Cytokine &amp; Supportive Oncology</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-792-7966</phone>
      <email>svadhanr@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

